MicronJet 600 Needle ישראל - עברית - Ministry of Health

micronjet 600 needle

nanopass technologies ltd. - אחות - הזרקה תוך עורית

מרוקן ישראל - עברית - Ministry of Health

מרוקן

taro pharmaceutical industries ltd - macrogols; potassium chloride; sodium bicarbonate; sodium chloride - אבקה להכנת תמיסה - macrogols 315.0 g; potassium chloride 1.1175 g; sodium bicarbonate 4.2840 g; sodium chloride 8.4240 g - mineral salts in combination - mineral salts in combination - bowel cleansing prior to colonoscopy and barium enema x-ray examinations.

רגולקס ישראל - עברית - Ministry of Health

רגולקס

neopharm consumer products ltd, israel - polyethylene glycol 3350 - אבקה להכנת תרחיף - polyethylene glycol 3350 99.973 %w/w - macrogol - macrogol - treatment of constipation.

פרקסיפרין 0.4 מ"ל/ 3800 IU AXA ישראל - עברית - Ministry of Health

פרקסיפרין 0.4 מ"ל/ 3800 iu axa

glaxo smith kline (israel) ltd - nadroparin calcium 3800 iu / 0.4 ml - solution for injection - nadroparin - prophylactic treatment of venous thromboembolic disease during surgery for patients presenting with moderate or high risk. treatment of constituted deep vein thrombosis. prevention of coagulation in the extra corporeal circuit during heamodialysis. the prophylaxis of thromboembolic disorders in high risk medical patients (respiratory failure and/or respiratory infection and/or cardiac failure) hospitalised in intensive care unit.

פרקסיפרין 0.3 מ"ל / 2850 AXa IU ישראל - עברית - Ministry of Health

פרקסיפרין 0.3 מ"ל / 2850 axa iu

glaxo smith kline (israel) ltd - nadroparin calcium 2850 iu / 0.3 ml - solution for injection - nadroparin - prophylactic treatment of venous thromboembolic disease during surgery for patients presenting with moderate or high risk. treatment of constituted deep vein thrombosis. prevention of coagulation in the extra corporeal circuit during haemodialysis. the prophylaxis of thromboembolic disorders in high risk medical patients (respiratory failure and/or respiratory infection and/or cardiac failure) hospitalised in intensive care unit.

פרקסיפרין 0.6 מ"ל/ 5700 IU AXA ישראל - עברית - Ministry of Health

פרקסיפרין 0.6 מ"ל/ 5700 iu axa

glaxo smith kline (israel) ltd - nadroparin calcium 5700 iu / 0.6 ml - solution for injection - nadroparin - prophylactic treatment of venous thromboembolic disease during surgery for patients presenting with moderate or high risk. treatment of constituted deep vein thrombosis. prevention of coagulation in the extra corporeal circuit during haemodialysis. the prophylaxis of thromboembolic disorders in high risk medical patients (respiratory failure and/or respiratory infection and/or cardiac failure) hospitalised in intensive care unit.

פרקסיפרין 0.8 מ"ל/7600 IU AXa ישראל - עברית - Ministry of Health

פרקסיפרין 0.8 מ"ל/7600 iu axa

glaxo smith kline (israel) ltd - nadroparin calcium 7600 iu / 0.8 ml - solution for injection - nadroparin - prophylactic treatment of venous thromboembolic disease during surgery for patients presenting with moderate or high risk. treatment of constituted deep vein thrombosis. prevention of coagulation in the extra corporeal circuit during haemodialysis. the prophylaxis of thromboembolic disorders in high risk medical patients (respiratory failure and/or respiratory infection and/or cardiac failure) hospitalised in intensive care unit.

סימביקורט טורבוהלר 1604.5 מקגמנה ישראל - עברית - Ministry of Health

סימביקורט טורבוהלר 1604.5 מקגמנה

astrazeneca (israel) ltd - budesonide micronized; formoterol fumarate - אבקה לשאיפה - budesonide micronized 160 mcg/dose; formoterol fumarate 4.5 mcg/dose - formoterol and budesonide - formoterol and other drugs for obstructive airway diseases - asthma symbicort turbuhaler is indicated in the regular treatment of asthma in adults and adolescents age 12 years and above where use of a combination (inhaled corticosteroid and long acting beta-agonist) is appropriate: - patients not adequately controlled with inhaled corticosteroids and " as needed" inhaled short acting beta2- agonists. or - patients already adequately controlled on both inhaled corticosteroids and long acting beta2- agonists. copd symptomatic treatment of patients with severe copd (fev1 < 50 % predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular therapy with long-acting bronchodilators.

סימביקורט טורבוהלר 804.5 מקגמנה ישראל - עברית - Ministry of Health

סימביקורט טורבוהלר 804.5 מקגמנה

astrazeneca (israel) ltd - budesonide micronized; formoterol fumarate - אבקה לשאיפה - budesonide micronized 80 mcg/dose; formoterol fumarate 4.5 mcg/dose - formoterol and budesonide - formoterol and other drugs for obstructive airway diseases - symbicort turbuhaler is indicated in the regular treatment of asthma where use of a combination (inhaled corticosteroid and long acting beta-agonist) is appropriate: - patients not adequaterly controlled with inhaled corticosteroids and " as needed" inhaled short acting beta2- agonists. - or patients already adequately controlled on both inhaled corticosteroids and long acting beta2- agonists. note: symbicort turbuhaler 80/4.5 mcg/dose is not appropriate in patients with severe asthma.